I
10.03
-0.03 (-0.30%)
| Previous Close | 10.06 |
| Open | 10.07 |
| Volume | 3,757,398 |
| Avg. Volume (3M) | 1,144,520 |
| Market Cap | 385,034,624 |
| Price / Sales | 8.63 |
| Price / Book | 0.480 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -448.03% |
| Diluted EPS (TTM) | -3.32 |
| Total Debt/Equity (MRQ) | 0.86% |
| Current Ratio (MRQ) | 12.62 |
| Operating Cash Flow (TTM) | -98.18 M |
| Levered Free Cash Flow (TTM) | -64.35 M |
| Return on Assets (TTM) | -14.47% |
| Return on Equity (TTM) | -23.07% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | iTeos Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.5
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.13% |
| % Held by Institutions | 90.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Asset Management Llc | 31 Mar 2025 | 2,738,785 |
| Mpm Bioimpact Llc | 31 Mar 2025 | 1,745,943 |
| Vestal Point Capital, Lp | 31 Mar 2025 | 900,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (HC Wainwright & Co., 358.62%) | Buy |
| Median | 12.00 (19.64%) | |
| Low | 8.00 (JP Morgan, -20.24%) | Hold |
| Average | 16.50 (64.51%) | |
| Total | 2 Buy, 4 Hold | |
| Avg. Price @ Call | 8.38 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 28 May 2025 | 12.00 (19.64%) | Hold | 10.06 |
| Wells Fargo | 28 May 2025 | 12.00 (19.64%) | Hold | 10.06 |
| 14 May 2025 | 13.00 (29.61%) | Buy | 7.60 | |
| Leerink Partners | 14 May 2025 | 9.00 (-10.27%) | Hold | 7.60 |
| Piper Sandler | 14 May 2025 | 12.00 (19.64%) | Buy | 7.60 |
| JP Morgan | 13 May 2025 | 8.00 (-20.24%) | Hold | 7.85 |
| 06 Mar 2025 | 15.00 (49.55%) | Buy | 7.10 | |
| HC Wainwright & Co. | 06 Mar 2025 | 46.00 (358.62%) | Buy | 7.10 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |